HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation

Table 4

HCC Characteristics for transplanted patients.

	HCV (N=30)	Non-HCV; (N=16)	P Value
Within Milan Pre-Transplant, N (%)	12 (40.0)	8 (50.0)	P=0.525
Within UCSF Pre-Transplant, N (%)	14 (46.7)	12 (75.0)	P=0.041
Listing:
AFP (ug/L), mean±SD [range]	17.3±23.5	8.8±14.0	P=0.211
Number of Tumors, mean±SD [range]	1.4±2.2	0.7±0.8	P=0.198
Total Tumor Volume (cm^3), mean±SD [range]	6.4±10.8	5.4±7.5	P=0.761
Last Values Prior to Transplant:
AFP(ug/L), mean±SD [range]	39.1±76.8	4.8±3.3	P=0.082
Total Tumor Volume (cm^3), mean±SD [range]	7.3±16.9	4.3±10.0	P=0.524
Explant Characteristics:
Within Milan, N (%)	19 (63.3)	11 (68.8)	P=0.721
Number of Tumors, mean±SD [range]	4.5±6.8	1.9±2.6	P=0.152
Total Tumor Volume (cm^3), mean±SD [range]	14.5±27.2	19.9±31.9	P=0.550
Histological Grade, N (%)
Necrotic	3 (10.0)	3 (18.8)
Well differentiated	3 (10.0)	3 (18.8)
Moderately differentiated	20 (66.7)	8 (50.0)
Poorly differentiated	4 (13.3)	2 (12.5)
Microvascular invasion, N (%)	3 (10.0)	1 (6.3)
Pre-Transplant Therapy, N (%)
None	5 (16.7)	4 (25.0)
Alcohol Ablation	1 (3.3)	1 (6.3)
Radiofrequency Ablation	16 (53.3)	9 (56.3)
TACE	18 (60.0)	6 (37.5)
SIRT	4 (13.3)	1 (6.3)
Resection	0	2 (12.5)
mTOR Inhibitor Post-Transplant, N (%)
2 months post-transplant	19 (63.3)	9 (64.3)	P=0.386
1 year post-transplant	14 (51.9)	9 (60.0)	P=0.739
HCC Recurrence among HCV+ LT Patients
Pre-LT SVR (N=3):
Time to recurrence post-LT, days	144, 442, 521
Location of recurrence	Multifocal, Lung, Lung
HCC Treatment	Sorafenib, None, None
Post-LT SVR (N=2):
Time to recurrence post-LT, days	375, 674
Location of recurrence	Lung, Liver Allograft
HCC Treatment	None, RFA